Xgeva Improves Survival Over Zometa in Advanced Lung Cancer (November 28, 2012)
Patients with advanced lung cancer experienced modest improvement in survival when they received bone-targeted therapy with Xgeva® (denosumab) instead of Zometa® (zoledronic acid), according to the results... Continue Reading
The targeted therapy Xalkori® (crizotinib) is superior to standard chemotherapy for the treatment of patients with advanced, ALK-positive non-small cell lung cancer, according to the results of a phase... Continue Reading
Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study published... Continue Reading
For some elderly patients with locally advanced non-small cell lung cancer (NSCLC), combination chemoradiotherapy provides a clinically significant benefit over radiotherapy alone, according to the results... Continue Reading
Two studies presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois shed new light on the best way to treat non-small cell lung cancer (NSCLC)—one... Continue Reading
Initial treatment with the targeted drug afatinib prolongs progression-free survival in patients with EGFR-positive advanced lung cancer when compared with standard chemotherapy, according to the results... Continue Reading
The addition of Avastin (bevacizumab) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) did not improve survival rates in patients over age 65 with advanced NSCLC, according to... Continue Reading
Among patients with Stage III non-small cell lung cancer, treatment with a higher dose of radiation therapy does not result in better overall survival than a standard dose of radiation therapy. These results... Continue Reading
The targeted drug Xalkori™ (crizotinib) has been approved by the US Food and Drug Administration for the treatment of advanced non-small lung cancer that has an abnormal version of the ALK gene. Lung... Continue Reading
Compared with the demographics of lung cancer in the United States, the elderly, minorities, and women remain vastly under-represented in lung cancer clinical trials. These results were presented at the... Continue Reading